SSGJ-707 + carboplatin + pemetrexed

SSGJ-707 + carboplatin + pemetrexed is a **pharmaceutical combination regimen** currently under investigation for advanced solid tumors, notably non-small cell lung cancer (NSCLC) and metastatic colorectal cancer. - **SSGJ-707** is an investigational bispecific antibody designed to target both **programmed cell death protein-1 (PD-1)** and **vascular endothelial growth factor (VEGF)**, developed on the CLF2 platform by 3SBio. It aims to enhance anti-tumor immune response (via PD-1 inhibition) while simultaneously inhibiting tumor angiogenesis (via VEGF inhibition)[1][5][7]. - **Carboplatin** is a platinum-based chemotherapy agent inducing DNA crosslinks and apoptosis by interfering with DNA repair mechanisms in rapidly growing cancer cells[6]. - **Pemetrexed** is an antimetabolite chemotherapy (also known as Alimta) that inhibits thymidylate synthase and several other folate-dependent enzymes, thereby preventing DNA synthesis and cellular replication in tumor cells[6]. This regimen is administered intravenously and is being explored for efficacy and safety primarily in NSCLC and metastatic colorectal cancer, often as first-line treatment for patients with advanced disease.